.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Cerilliant
Harvard Business School
Dow
Mallinckrodt
Healthtrust
Federal Trade Commission
Citi
Moodys
Merck

Generated: June 23, 2017

DrugPatentWatch Database Preview

ORFADIN Drug Profile

« Back to Dashboard

Which patents cover Orfadin, and when can generic versions of Orfadin launch?

Orfadin is a drug marketed by Swedish Orphan and is included in two NDAs. There is one patent protecting this drug.

This drug has twenty patent family members in twenty countries.

The generic ingredient in ORFADIN is nitisinone. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nitisinone profile page.

Summary for Tradename: ORFADIN

Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list65
Clinical Trials: see list10
Patent Applications: see list158
Drug Prices:see details
DailyMed Link:ORFADIN at DailyMed

Pharmacology for Tradename: ORFADIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-001Jan 18, 2002RXYesNo► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-004Jun 13, 2016RXYesYes► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 2002RXYesNo► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 2002RXYesYes► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
SUSPENSION;ORAL206356-001Apr 22, 2016RXYesYes9,301,932► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ORFADIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 20025,550,165► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 20025,550,165► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-001Jan 18, 20025,006,158► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 20025,006,158► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 20025,006,158► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ORFADIN

Country Document Number Estimated Expiration
Canada2838039► Subscribe
Russian Federation2014101990► Subscribe
Denmark2723320► Subscribe
Russian Federation2605301► Subscribe
San MarinoT201600097► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ORFADIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB05/030United Kingdom► SubscribePRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
00198Netherlands► SubscribePRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201
C0024France► SubscribePRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Citi
Fuji
Daiichi Sankyo
Argus Health
Boehringer Ingelheim
Deloitte
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot